Transthyretin Amyloidosis (ATTR)
Heart Failure Society of America (HFSA) 2026
Congress Details
October 9-12, 2026
Phoenix, AZ, USA
The material below is provided to support scientific exchange and pertains to select congress resources. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.
All congress materials are copyrighted by Alnylam. Permission is required to copy or distribute.
For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.
Agenda
10 October, 2026
Presentation Type
Time
Location
Title
Presenter
Ronald Witteles
Stanford University School of Medicine
CA, USA
Presentation Type
Time
Location
Title
Presenter
Ronald Witteles
Stanford University School of Medicine
CA, USA
Presentation Type
Time
Location
Title
Presenter
Ronald Witteles
Stanford University School of Medicine
CA, USA
11 October, 2026
Presentation Type
Time
Location
Title
Presenter
Sumeet Mitter
Inova Schar Heart and Vascular
VA,USA
Related Materials
Transthyretin Amyloidosis (ATTR)
Vutrisiran in Transthyretin Amyloidosis: A Pooled Safety Analysis of HELIOS-A and HELIOS-B
JACC: Advances
Transthyretin Amyloidosis (ATTR)
Effects of Vutrisiran on Cardiac Structure and Function in Patients with Transthyretin Amyloidosis with Cardiomyopathy: Secondary Outcomes of the HELIOS-B Trial
Nature Medicine
Transthyretin Amyloidosis (ATTR)
Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B
Journal of the American College of Cardiology
